Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.28
CORI's Cash-to-Debt is ranked lower than
84% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CORI: 1.28 )
Ranked among companies with meaningful Cash-to-Debt only.
CORI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.79 Max: 1.44
Current: 1.28
0.08
1.44
Equity-to-Asset 0.29
CORI's Equity-to-Asset is ranked lower than
93% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CORI: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
CORI' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.28  Med: 0.06 Max: 0.35
Current: 0.29
-3.28
0.35
Debt-to-Equity 1.89
CORI's Debt-to-Equity is ranked lower than
100% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CORI: 1.89 )
Ranked among companies with meaningful Debt-to-Equity only.
CORI' s Debt-to-Equity Range Over the Past 10 Years
Min: -118.07  Med: 1.89 Max: 24.08
Current: 1.89
-118.07
24.08
Piotroski F-Score: 4
Altman Z-Score: 0.04
Beneish M-Score: -2.94
WACC vs ROIC
9.82%
-269.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -119.18
CORI's Operating Margin % is ranked higher than
50% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CORI: -119.18 )
Ranked among companies with meaningful Operating Margin % only.
CORI' s Operating Margin % Range Over the Past 10 Years
Min: -119.18  Med: -23.68 Max: 2.39
Current: -119.18
-119.18
2.39
Net Margin % -145.61
CORI's Net Margin % is ranked lower than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CORI: -145.61 )
Ranked among companies with meaningful Net Margin % only.
CORI' s Net Margin % Range Over the Past 10 Years
Min: -145.61  Med: -27.6 Max: -12.7
Current: -145.61
-145.61
-12.7
ROE % -590.68
CORI's ROE % is ranked lower than
98% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CORI: -590.68 )
Ranked among companies with meaningful ROE % only.
CORI' s ROE % Range Over the Past 10 Years
Min: -590.68  Med: -156.52 Max: -120.75
Current: -590.68
-590.68
-120.75
ROA % -60.59
CORI's ROA % is ranked lower than
68% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CORI: -60.59 )
Ranked among companies with meaningful ROA % only.
CORI' s ROA % Range Over the Past 10 Years
Min: -60.59  Med: -34.17 Max: -14.63
Current: -60.59
-60.59
-14.63
ROC (Joel Greenblatt) % -298.81
CORI's ROC (Joel Greenblatt) % is ranked higher than
55% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CORI: -298.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CORI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -298.81  Med: -57.13 Max: -2.36
Current: -298.81
-298.81
-2.36
3-Year Revenue Growth Rate -44.50
CORI's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CORI: -44.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CORI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -22.25 Max: -44.5
Current: -44.5
3-Year EBITDA Growth Rate 22.20
CORI's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CORI: 22.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CORI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.1 Max: 22.2
Current: 22.2
0
22.2
3-Year EPS without NRI Growth Rate -11.70
CORI's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CORI: -11.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CORI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.85 Max: -11.7
Current: -11.7
GuruFocus has detected 3 Warning Signs with Corium International Inc $CORI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CORI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CORI Guru Trades in

Q4 2016

CORI Guru Trades in Q4 2016

Chuck Royce 177,864 sh (New)
» More
Q1 2017

CORI Guru Trades in Q1 2017

Chuck Royce 548,464 sh (+208.36%)
» More
Q2 2017

CORI Guru Trades in Q2 2017

Jim Simons 181,400 sh (New)
Chuck Royce 435,064 sh (-20.68%)
» More
» Details

Insider Trades

Latest Guru Trades with CORI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CCXI, NAS:GERN, NAS:CRVS, NAS:RARX, NAS:MRSN, NAS:CRBP, NAS:BSTC, NAS:NLNK, NAS:NVAX, NAS:CNCE, AMEX:BTX, AMEX:XXII, NAS:CLDX, OTCPK:AXIM, OTCPK:DTHR, NAS:SELB, NAS:GLYC, NAS:BLCM, NAS:IDRA, NAS:CBAY » details
Traded in other countries:6CU.Germany,
Headquarter Location:USA
Corium International Inc is a commercial stage biopharmaceutical company. The Company develops, manufactures and commercializes specialty pharmaceutical products that leverage its experience in transdermal and transmucosal delivery systems.

Corium International Inc is incorporated in Delaware in 1995 as Corium Corporation and in 1996 as Converting Systems, Inc. In 2002, these companies were merged and re-named Corium International, Inc. and its place of incorporation changed to Delaware. The Company is a commercial stage biopharmaceutical company. It develops, manufactures and commercializes specialty pharmaceutical products. The Company has developed six marketed products in the prescription drug and consumer markets, and it is the sole commercial supplier of each of those products for its marketing partners. These marketed products are Clonidine Transdermal Delivery System, or TDS, Fentanyl TDS and four Crest Advanced Seal Whitestrips products. The Company is developing two additional products utilizing its proprietary technologies that it plans to advance into Phase 2 trials in 2014 and 2015. Some of its products or product candidates contain controlled substances, the making, use, sale, importation and distribution of which are subject to regulation by state, federal and foreign law enforcement and other regulatory agencies.

Top Ranked Articles about Corium International Inc

Corium to Present at Upcoming Healthcare Conferences
Corium to Report Third Quarter Fiscal 2017 Financial Results on Thursday, August 3, 2017
Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex™ Donepezil Transdermal System at Alzheimer's Association International Conference® 2017
Corium to Present at the Jefferies 2017 Global Healthcare Conference 
Corium Announces Closing of Follow-On Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Corium Prices Follow-On Offering of Common Stock
Corium Announces Proposed Public Offering of Common Stock
Corium Reports Positive Preliminary Results in Alzheimer’s Clinical Study
Corium to Report Preliminary Results from Corplex Donepezil Pilot Study and Second Quarter Fiscal 2017 Financial Results Before Market Open on Thursday, May 11, 2017
Corium to Present at the 16th Annual Needham Healthcare Conference

MENLO PARK, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:00 AM EDT. 
A live audio webcast of Corium’s presentation may be accessed here or by visiting “Events & Presentations” in the Investors section of the Company’s website at www.coriumgroup.com.  The webcast will be archived on the Corium website for two weeks following the presentation. About Corium Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems.  Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease.  Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble.  The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.  The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners.  For further information, please visit www.coriumgroup.com. Corplex™ and MicroCor® are registered trademarks of Corium International, Inc. Source: Corium
Investor and Media Contact:
SMP Communications
Susan M. Pietropaolo
[email protected]
(201) 923-2049

Read more...

Ratios

vs
industry
vs
history
PB Ratio 13.85
CORI's PB Ratio is ranked lower than
99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CORI: 13.85 )
Ranked among companies with meaningful PB Ratio only.
CORI' s PB Ratio Range Over the Past 10 Years
Min: 3.8  Med: 8.61 Max: 97.4
Current: 13.85
3.8
97.4
PS Ratio 8.91
CORI's PS Ratio is ranked higher than
69% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CORI: 8.91 )
Ranked among companies with meaningful PS Ratio only.
CORI' s PS Ratio Range Over the Past 10 Years
Min: 0.71  Med: 3.02 Max: 9.01
Current: 8.91
0.71
9.01
EV-to-EBIT -10.22
CORI's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CORI: -10.22 )
Ranked among companies with meaningful EV-to-EBIT only.
CORI' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.3  Med: -5.95 Max: 53.9
Current: -10.22
-43.3
53.9
EV-to-EBITDA -10.81
CORI's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CORI: -10.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -738.4  Med: -6.4 Max: 26.8
Current: -10.81
-738.4
26.8
EV-to-Revenue 12.12
CORI's EV-to-Revenue is ranked higher than
60% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CORI: 12.12 )
Ranked among companies with meaningful EV-to-Revenue only.
CORI' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.4 Max: 9.4
Current: 12.12
2.1
9.4
Current Ratio 7.04
CORI's Current Ratio is ranked higher than
60% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CORI: 7.04 )
Ranked among companies with meaningful Current Ratio only.
CORI' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 5.5 Max: 9.51
Current: 7.04
1.07
9.51
Quick Ratio 6.80
CORI's Quick Ratio is ranked higher than
60% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CORI: 6.80 )
Ranked among companies with meaningful Quick Ratio only.
CORI' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 5.19 Max: 9.13
Current: 6.8
0.85
9.13
Days Inventory 35.74
CORI's Days Inventory is ranked higher than
82% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CORI: 35.74 )
Ranked among companies with meaningful Days Inventory only.
CORI' s Days Inventory Range Over the Past 10 Years
Min: 29.78  Med: 36.4 Max: 46.08
Current: 35.74
29.78
46.08
Days Sales Outstanding 55.06
CORI's Days Sales Outstanding is ranked higher than
72% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CORI: 55.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.72  Med: 35.85 Max: 55.06
Current: 55.06
22.72
55.06
Days Payable 78.03
CORI's Days Payable is ranked lower than
51% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CORI: 78.03 )
Ranked among companies with meaningful Days Payable only.
CORI' s Days Payable Range Over the Past 10 Years
Min: 25.76  Med: 34.79 Max: 78.03
Current: 78.03
25.76
78.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -57.00
CORI's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CORI: -57.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -57  Med: -28.5 Max: 0
Current: -57
-57
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 53.45
CORI's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CORI: 53.45 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CORI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.3  Med: 23.2 Max: 54
Current: 53.45
12.3
54
Price-to-Tangible-Book 18.75
CORI's Price-to-Tangible-Book is ranked lower than
99.99% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CORI: 18.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CORI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.28  Med: 13.04 Max: 21.62
Current: 18.75
7.28
21.62
Price-to-Median-PS-Value 2.95
CORI's Price-to-Median-PS-Value is ranked lower than
81% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CORI: 2.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CORI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 0.93 Max: 2.98
Current: 2.95
0.31
2.98
Earnings Yield (Greenblatt) % -9.81
CORI's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CORI: -9.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CORI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -36.7  Med: -15.05 Max: 2.6
Current: -9.81
-36.7
2.6

More Statistics

Revenue (TTM) (Mil) $30.34
EPS (TTM) $ -1.73
Beta1.13
Short Percentage of Float14.90%
52-Week Range $2.67 - 10.52
Shares Outstanding (Mil)35.74

Analyst Estimate

Sep17 Sep18
Revenue (Mil $)
EPS ($) -1.67 -1.19
EPS without NRI ($) -1.67 -1.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CORI

Headlines

Articles On GuruFocus.com
Corium to Present at Upcoming Healthcare Conferences Sep 05 2017 
Corium to Report Third Quarter Fiscal 2017 Financial Results on Thursday, August 3, 2017 Jul 27 2017 
Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex™ Donepezil Transder Jul 18 2017 
Corium to Present at the Jefferies 2017 Global Healthcare Conference  Jun 01 2017 
Corium Announces Closing of Follow-On Offering of Common Stock and Full Exercise of Underwriters†May 31 2017 
Corium Prices Follow-On Offering of Common Stock May 25 2017 
Corium Announces Proposed Public Offering of Common Stock May 24 2017 
Corium Reports Positive Preliminary Results in Alzheimer’s Clinical Study May 11 2017 
Corium to Report Preliminary Results from Corplex Donepezil Pilot Study and Second Quarter Fiscal 20 May 09 2017 
Corium to Present at the 16th Annual Needham Healthcare Conference Mar 27 2017 

More From Other Websites
Corium to Present at Upcoming Healthcare Conferences Sep 05 2017
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole Aug 24 2017
Edited Transcript of CORI earnings conference call or presentation 3-Aug-17 9:00pm GMT Aug 12 2017
Corium reports 3Q loss Aug 04 2017
Corium Reports Recent Corporate Highlights and Financial Results for Third Quarter Fiscal 2017 Aug 03 2017
Investor Network: Corium International, Inc. to Host Earnings Call Aug 03 2017
Corium to Report Third Quarter Fiscal 2017 Financial Results on Thursday, August 3, 2017 Jul 27 2017
Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex™ Donepezil Transdermal... Jul 18 2017
Corium International (CORI) Catches Eye: Stock Jumps 11.9% Jul 07 2017
Corium to Present Clinical Results from Pilot Bioequivalence Study of Once-weekly Corplex™... Jul 06 2017
Corium Joins Russell 3000® Index Jun 26 2017
ETFs with exposure to Corium International, Inc. : May 25, 2017 May 25 2017
Corium International, Inc. :CORI-US: Earnings Analysis: Q2, 2017 By the Numbers : May 24, 2017 May 24 2017
AxoGen (AXGN) Shows Strength: Stock Adds 6.1% in Session May 22 2017
Edited Transcript of CORI earnings conference call or presentation 11-May-17 12:30pm GMT May 18 2017
Can The Uptrend Continue for Corium International (CORI)? May 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}